Major strides in pancreatic cancer give ‘actual reasons for hope’

November 19, 2018  //  FOUND IN: News,

When the five-year survival rate for pancreatic cancer hit 9 percent last year, it represented a near doubling from just five years earlier.

While progress is exciting, much work remains to be done.

“There’s actual reason for hope now. For the longest time, we were throwing around the word ‘hope,’ but now we have scientific reason for hope,” said Clifford Cho, M.D., a pancreatic cancer surgeon at the Rogel Cancer Center. “I feel there’s momentum right now. Scientists are working tremendously hard on this question. There is an accelerating momentum. Our patients deserve that.”

Better funding throughout the last decade from foundations and advocacy groups has helped move the field forward. Additionally, working collaboratively within and across institutions, researchers are gaining new understandings of pancreatic cancer and can now simulate it better in laboratory models.

The result: incremental, yet significant improvements in surgery, radiation therapy and chemotherapy that have some patients with advanced disease living for years instead of months.

And on the horizon: a determination among researchers to manipulate the immune system so that pancreatic cancer patients can benefit from the immunotherapy treatments revolutionizing other hard-to-treat cancers.

“Immune therapy is the future. For the past 20 years, we’ve been using chemotherapy regimens with minor benefits. We need more tolerable medicines that allow for a good quality of life,” said Howard Crawford, Ph.D., director of the Pancreas Disease Initiative and professor of molecular and integrative physiology and internal medicine. “Pancreatic cancer has been one of the most difficult cancers, no question.”

The statistics are bleak. About 55,440 people will be diagnosed with pancreatic cancer in 2018 and about 44,330 will die from the disease, according to the American Cancer Society. And a recent study predicted pancreatic cancer will become the second-leading cause of cancer-related death in the U.S. by 2020. It’s currently third.

Early detection a challenge

The pancreas is an organ about the size of a hand that makes insulin and enzymes for digestion. It sits across the upper abdomen, behind the lower part of the stomach — more or less in the middle of your body. And that makes it really hard to detect cancer.

Pancreatic cancer causes few symptoms and when they emerge, it’s often when the cancer is no longer curable through surgery.

“Patients don’t have symptoms early on and almost always present with advanced disease,” said Vaibhav Sahai, MBBS, M.S., assistant professor of hematology and oncology at U-M.

The most common symptoms — back pain, weight loss, yellowing of the eyes or skin — are general enough to blame on other problems.

“We need to do a better job of educating people and providers to be more alert when symptoms arise. Too many people are not having their symptoms recognized,” said Timothy Frankel, M.D., assistant professor of surgery at U-M.

Screenings, risk factors remain elusive

Currently, there are no proven effective screening tests for pancreatic cancer. Research is focused on using ultrasound or finding factors in the blood or urine that might serve as early markers.

Rogel Cancer Center researchers are working to detect circulating tumor cells or RNA markers of pancreatic cancer in the blood. Others are developing a scaffold device that could be inserted in the body to attract cancer cells, potentially triggering an early warning of a developing tumor.

But the question is: Who should get these screenings? A small proportion of pancreatic cancers involve an inherited defect in genes such as BRCA1BRCA2 or PALB2. This is likely around 5 percent of patients.

There are a few other indications that might suggest high risk, including other rare inherited gene defects, a first-degree relative with pancreatic cancer, and a new diagnosis of diabetes in middle-aged people without obesity. The only controllable risk factor is cigarette smoking.

Beyond these, little is known about why someone has a high risk of developing pancreatic cancer.

“We need both better screening and better treatments. It’s not either/or,” said Marina Pasca di Magliano, Ph.D., associate professor of surgery and of cell and developmental biology at U-M. “Even if we have great screening tools, we will also need effective therapies.”

Why pancreatic cancer is so challenging

Several unique characteristics make pancreatic cancer especially difficult to treat.

It grows in an unusual pattern in which tentacles extend into the nerves and blood vessels. This creates challenges for surgeons and radiation oncologists who must work around these critical structures. It’s one reason only 20 percent of patients can have surgery.

It’s also very quick to metastasize.

“Even when we find it at the smallest size, sometimes it’s spread throughout the body,” Frankel said.

And when patients can have surgery, the cancer frequently returns. Only 1 in 4 patients survive long-term after surgery.

Once the cancer spreads, it spreads everywhere. So when it reaches the liver, for example, it doesn’t usually form one tumor — it forms dozens of tumors all throughout the organ, making it impossible to remove with surgery.

But improvements in imaging, surgical techniques and anesthesia mean more patients can benefit from surgery. Chemotherapy and radiation can also shrink the tumor, unraveling it from critical structures or making it small enough that the patient can have surgery.

Clifford Cho, M.D., right: “If you look at pancreatic cancer under a microscope, it doesn’t look like cancer.”

Limited success with chemotherapy

Surgery and radiation are often coupled with chemotherapy to kill any cancer remaining in the body. Recent improvements in chemotherapy have improved outcomes. But another unusual hallmark of pancreatic cancer limits success.

“If you look at pancreatic cancer under a microscope, it doesn’t look like cancer. It looks like scar tissue with little spots of cancer,” Cho said.

This scar tissue, or fibrosis, increases pressure inside the tumor and causes blood vessels to collapse. When that happens, the chemotherapy drugs don’t actually get into the tumor.

“If the tumor doesn’t see the chemotherapy, it doesn’t really do anything,” Crawford said. “All it does is make the patient sick.”

Research at the Rogel Cancer Center is looking at how to decrease fibrosis and diminish pressure on the blood vessels. Current clinical trials open at U-M are investigating approved drugs — both novel and existing — in new combinations to address this.

“Typically, scar tissue is quiescent, but these are active and secreting a lot of signals. It’s similar to scar tissue but different,” Pasca di Magliano said. “People are starting to unravel what these cells do.”

Better research models yield major strides

Progress really began to open up in 2003 when researchers finally created a good mouse model of pancreatic cancer. Previous models struggled to express the correct cancer-driving genes or express them at the right level, so cancer in a mouse didn’t behave the same as cancer in a human.

Now, the pancreatic cancer mouse model is considered one of the closest to replicating human disease.

“We went from having no good model to having one of the best. The models have really led to the field exploding,” Pasca di Magliano said.

Researchers also began to improve upon traditional cell lines, which reflected only the tumor cells — but not all of the other complicated systems at play in the microenvironment.

Another approach is to take tumors directly from patients and implant them into mice. These models can also capture key aspects of human pancreatic cancer for testing in the laboratory.

But because so few patients can have surgery, tissue samples are limited.

A tricky target

The most common genetic driver of pancreatic cancer comes from mutations in the KRAS gene, which account for 90 percent of pancreas tumors. This looked like the perfect target for treatment.

Instead, attempts to develop targeted therapies have failed. As of today, KRAS is considered undruggable.

“The driver mutation for this cancer has not been targetable. If you can’t target the driver, killing the passenger will not produce a cure,” Sahai said, explaining why current targeted therapies ultimately fail.

KRAS is like a small, tight ball. It leaves no surface or pocket where an inhibitor can notch its way in.

“Knowing we don’t have an agent to block KRAS, we are trying to understand what happens downstream,” Pasca di Magliano said. She’s working with Sahai to identify a combination of existing drugs that might be viable in a clinical trial.

The promise of immunotherapy

What has researchers truly excited is immunotherapy. Harnessing the immune system to attack cancer has led to cures in advanced melanoma and lung cancer — cancers that previously had outcomes as bleak as pancreatic cancer.

So far, immunotherapy has been largely ineffective in pancreatic cancer. Still, researchers think they can solve it.

“The ability of the immune system to see pancreatic cancer is really zero,” Cho said. “But this is not insurmountable. Are there things we can do to make it more noticeable to the immune system?”

Human immune systems are wired to kill any foreign cells, including cancer cells. But cancer is wily. It finds ways to trick the immune system into thinking it belongs. The immunotherapy drugs that have worked in melanoma, immune checkpoint inhibitors, block this process.

But in pancreatic cancer, there are multiple mechanisms blocking the immune system.

“It’s been hard to get immune cells to go into the pancreas. We don’t see a lot of T cells, the killer immune cells,” said Ted Lawrence, M.D., Ph.D., Isadore Lampe Professor and chair of radiation oncology at U-M. “Immune checkpoint inhibitors won’t work if T cells aren’t getting there.”

He and collaborators Meredith Morgan, Ph.D., associate professor of radiation oncology, and Weiping Zou, M.D., Ph.D., Charles B. de Nancrede Professor of Surgery, Immunology and Biology, are working on an approach combining radiation with a new drug that affects DNA repair.

The idea: trick the cell into thinking a virus is attacking. That then triggers the immune system, which would open the door for an immune checkpoint inhibitor to do its job. The approach has worked well in the lab, and plans for a clinical trial are underway.

Other groups are using techniques to analyze each individual cell to get a comprehensive view of what’s happening within the tumor. They hope this leads to an understanding of what signals are blocking the immune system and what vulnerable points to go after.

“If we are going to get to a cure or major advance for pancreatic cancer, it’s going to be through immunotherapy,” Frankel said.

Exploiting how cells use energy

One potential vulnerability is in the metabolism, or the way cells use energy.

The body sends a limited amount of fuel to both the cancer and the immune system. The immune system needs fuel to kill the cancer. But the cancer gobbles up the nutrients, taking more than it needs.

“Tumors find a dozen different ways to keep the immune cells away — masking themselves, eating the nutrients,” said Costas Lyssiotis, Ph.D., assistant professor of molecular and integrative physiology. “If you can block how cancer cells are eating the nutrients, then immune cells can use those nutrients.”

His lab has pinpointed several unique metabolic differences specific to the pancreas, and is developing drugs to exploit them. A clinical trial will open soon at the Rogel Cancer Center comparing chemotherapy alone versus chemotherapy plus a metabolomic drug that switches off two pathways of energy.

Boom in clinical trials holds promise

It’s one of many for pancreatic cancer patients, demonstrating how progress in understanding the disease’s biology has led to novel ideas for combining drugs to improve outcomes.

“We now have a wide range of clinical trials for pretty much any stage of pancreatic cancer,” Cho said. “This is how we learn what works or what doesn’t work.”

Combine this with a new approach researchers are calling phase minus-1, including animal models and human three-dimensional organoid models running at the same time. This design keeps the pipeline flowing from the lab to the clinic and back — a way to tweak and improve ideas as researchers gain more understanding of what works and what doesn’t.

Collaboration like this is key, researchers say — a plan of attack that includes reaching out to scientists at other institutions to pool data and patient samples. Crawford and Pasca di Magliano are part of an NIH-funded consortium of researchers from six top cancer centers across the country.

The network will look at factors in the tumor microenvironment that make pancreatic cancer unresponsive to immunotherapy treatments and consider how to use already FDA-approved drugs to make pancreatic cancer responsive to immune therapy.

“The pancreatic cancer field in general is a very collaborative group. This is such a bad disease. It doesn’t matter who makes progress,” Crawford said.

Advocacy groups, such as the Pancreatic Cancer Action Network, are stepping forward to support this research, generating more funding and drawing top scientists to this difficult field. It’s starting to lead to advances and also helping to generate more collaboration.

Still, financial backing remains a crucial but finite resource.

“We have an unlimited amount of ideas. If you want to make something happen, there needs to be money in place,” Lyssiotis said. “We each have hundreds of ideas. I’m funded to try 10 of them. Did I pick the right 10? If I had twice the funding, I could try twice as many ideas.”

Looking ahead, researchers are encouraged by extended survival from incremental advances, and the promise of immunotherapy could lead to a giant leap forward.

“I think we’re going to get to the point very soon where we make pancreatic cancer as treatable as other cancers,” Crawford said. “Patients can have quality of life and longevity that allows them to live out a normal life with cancer as a chronic disease. That would be a huge difference.”